What the FDA labels say about taking them together
Naloxegol and voriconazole
Voriconazole's FDA label of February 26, 2026 names naloxegol in its drug interactions section; the naloxegol label PlainMeds reads does not name voriconazole. The voriconazole label: “Contraindicated”
Check it at the source: the naloxegol FDA label on DailyMed (effective September 1, 2026, Averitas Pharma, Inc.); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the naloxegol label say about voriconazole?
Naloxegol's label (effective September 1, 2026) does not name voriconazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (MOVANTIK), Averitas Pharma, Inc., effective September 1, 2026 (SPL set 28596788-b73f-4247-85fc-3105f51fff5a), via openFDA; the full label on DailyMed
What does the voriconazole label say about naloxegol?
Voriconazole label, drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Naloxegol (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased which may Increase the Risk of Adverse Reactions; Prevention or Management Recommendations: Contraindicated
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), contraindicationsCoadministration of Voriconazole for injection with naloxegol is contraindicated because Voriconazole for injection may increase plasma concentrations of naloxegol which may precipitate opioid withdrawal symptoms [see Drug Interactions (7) ].
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Naloxegol (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased which may Increase the Risk of Adverse Reactions; Recommendations for Drug Dosage Adjustment/Comments: Contraindicated
Source: FDA drug label (Voriconazole, NDA208562), Xellia Pharmaceuticals USA LLC, effective January 11, 2023 (SPL set 9ec6eda2-2f15-423b-9ec6-819379a426e1), via openFDA
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Naloxegol | Voriconazole | |
|---|---|---|
| Labeled for | n/a | Fungal infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $14.61 per tablet 25 mg tablet | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once